DOCSLIB.ORG

Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/R) Formulation on WHO Model List of Essential Medicines for Children

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/R) Formulation on WHO Model List of Essential Medicines for Children Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion ......................................................................... 2 2. Antiretroviral therapy is recommended for all HIV-infected children, adolescents, and adults. ............................................................................................................................................... 2 3. Name of the focal point in WHO submitting the application: ............................................... 2 4. Name of the organization(s) consulted and/or supporting the application: .......................... 2 5. International Non-proprietary Name: ..................................................................................... 2 6. Formulation and strength proposed for inclusion:.................................................................. 2 7. International availability .......................................................................................................... 2 8. Whether listing is requested as an individual medicine or as an example of a therapeutic group: ............................................................................................................................................... 2 9. Information supporting public health relevance ..................................................................... 3 9.1 Epidemiological information on disease burden 3 9.2 Assessment of current use 3 9.3 Target population 4 10. Treatment details ................................................................................................................ 4 10.1 Reference to existing WHO guidelines 4 10.2 Dosage regimen, duration 4 Table 1: Recommended dosing of LPV/r oral granules by weight band to be taken twice daily ........ 5 11. Summary of comparative effectiveness in a variety of clinical settings .................................. 6 12. Comparative evidence on safety: ......................................................................................... 7 12.1 Estimate of total patient exposure to date 7 12.2 Description of adverse effects/reactions 7 12.3 Identification of variation in safety due to health systems and patient factors 7 12.4 Drug interactions requiring dose adjustment 7 13. Summary of available data on comparative cost and cost-effectiveness within the pharmacological class or therapeutic group: ................................................................................... 7 Table 2: Price per Unit and Price per Patient per Year for TDF/3TC/DTG and other First-Line Products ............................................................................................................................................................... 8 14. Summary of regulatory status of the medicine (in country of origin and preferably in other countries as well): ................................................................................................................... 8 15. Availability of pharmacopoieal standards: .......................................................................... 8 16. Proposed (new/adapted) text for the WHO Model Formulary .......................................... 9 Table 3: Recommended dosing of LPV/r granules by weight band to be taken twice daily ................ 9 17. References: Comprehensive reference list and in-text citations. ........................................ 9 1 1. Summary statement of proposal for inclusion This document proposes the inclusion of lopinavir/ritonavir oral granules formulation (LPV/r, 40mg/10mg) as part of a combination treatment of HIV infection among children living with HIV/AIDS in the WHO Essential Medicines List for Children (EMLc). Low dose ritonavir is included in this product, not for its intrinsic anti-retroviral activity, but because it inhibits the metabolic clearance of lopinavir. LPV/r in the dosage forms of tablets (400mg/100mg and 100mg/25mg), oral solution (80mg/20mg/mL), and oral pellets (40mg/10mg) are currently included in the EML and EMLc. 2. Antiretroviral therapy is recommended for all HIV-infected children, adolescents, and adults. 3. Name of the focal point in WHO submitting the application: Martina Penazzato, WHO/HTM/HIV/ATC 4. Name of the organization(s) consulted and/or supporting the application: Clinton Health Access Initiative, Inc (CHAI) 5. International Non-proprietary Name: Co-formulated lopinavir + ritonavir, ATC code: J05AR10 6. Formulation and strength proposed for inclusion: Each sachet contains 40mg of lopinavir and 10mg of ritonavir as oral granules. 7. International availability LPV/r oral granules are manufactured by Mylan Laboratories, Limited: Mylan Laboratories, Limited Robert J. Coury Global Center 1000 Mylan Blvd. Canonsburg, PA 15317 8. Whether listing is requested as an individual medicine or as an example of a therapeutic group: Listing is requested on the Model List of Essential Medicines for Children as a new formulation for LPV/r intended for pediatric use; it is an example of the therapeutic class of HIV protease inhibitors. Other members of this class of drugs may serve as alternatives, depending on quality, price and local availability. 2 9. Information supporting public health relevance 9.1 Epidemiological information on disease burden Despite an impressive reduction in mother to child transmission of HIV in recent years, 180,000 new pediatric infections occurred in 2017. There are now 1.8 million children living with HIV, the vast majority in sub-Saharan Africa. Evidence shows that in the absence of ART, over 50% of HIV- infected infants progress to AIDS and death by the age of 2 years1, but the introduction of pediatric ART has changed HIV infection in children from a life-threatening illness to a chronic but manageable infection. Despite recognition of the advantages of early treatment, pediatric treatment coverage still only reaches 52% of children eligible for treatment2 and in 2017 an estimated 110,000 HIV/AIDS related deaths occurred in children <15 years of age3. However, with increasing evidence about the beneficial effects of earlier ART initiation and the release of the 2016 WHO Consolidated Guidelines, new recommendations stress the need for early testing and treatment for all infants and children living with HIV.4 Scaling up early infant testing (including testing at birth) to identify perinatal transmission will allow many more infants to receive life-saving ARVs within the first few weeks of life. Since 2014 and as led by UNAIDS, the global community has set a target to end the AIDS epidemic by 2030, but the particular vulnerabilities of pediatric patients necessitate an even more ambitious goal - ending pediatric AIDS by 2020.5 This super fast-track target aim to reach 1.6 million children with ART by 2018. In order to successfully scale-up treatment of pediatric HIV infection, it is critical that ARV dosage forms appropriate for use in infant and young children are accessible, particularly in resource limiting settings. The availability of solid dosage forms has proven to be an advantage over liquid dosage forms in that they are more easily stored, ease administration, and support adherence in infants and young children. The WHO now recommends that for pediatric treatment, liquid dosage forms should be avoided when possible in favor of solid dosage forms, ideally dispersible, fixed-dose combination tablets if available. Recent years has seen the development of a variety of dosage forms for pediatric ARVs but, compared to the demand for adult ARVs, children account for just 5% of patients on ART, thereby rendering the global pediatric market smaller and more vulnerable to supply disruption. The Optimal Pediatric ARV Formulary and Limited-use List was first developed in 2011 to address this challenge and now provides guidance to streamline the selection of pediatric ARV dosage forms to those that conform to a list of criteria, including dosing flexibility, user-friendliness, optimization of supply chain management, and availability of quality assured products in resource limited settings. This Optimal Formulary/LUL is revised on a regular basis to reflect current WHO recommended regimens. LPV/r oral pellets and oral granules are currently listed as optimal formulations and are listed collectively as a “solid oral dosage form 40mg/10mg..”6 These two formulations are listed to be used with 2 NRTIs for alternative first-line or second-line treatment for infants and children below 10 kg or unable to swallow 100mg/25mg tablets whole. 9.2 Assessment of current use Estimates of current usage of LPV/r oral granules are not available as the formulation was only recently approved and added to the Optimal Formulary list. According to CHAI ARV market analysis, use of LPV/r in pediatric patients will remain at about 25% of the treated population for the next several years. The report notes that since late 2016, global demand for the LPV/r pellets has 3 outpaced supply, which has limited uptake in LMICs. However, increased production of LPV/r pellets and introduction of LPV/r oral granules should ease global supply constraints in the future.7 9.3 Target population Like the oral pellets, LPV/r oral granules are intended as alternate first-line treatment of HIV infection in pediatric patients younger than 3 years of age. LPV/r oral granules should not be administered to premature neonates (born one month or more before expected date
Load more

Recommended publications
  • KALETRA (Lopinavir/Ritonavir)
    HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS These highlights do not include all the information needed to use • Hypersensitivity to KALETRA (e.g., toxic epidermal necrolysis, Stevens- KALETRA safely and effectively. See full prescribing information for Johnson syndrome, erythema multiforme, urticaria, angioedema) or any of KALETRA. its ingredients, including ritonavir. (4) • Co-administration with drugs highly dependent on CYP3A for clearance KALETRA (lopinavir and ritonavir) tablet, for oral use and for which elevated plasma levels may result in serious and/or life- KALETRA (lopinavir and ritonavir) oral solution threatening events. (4) Initial U.S. Approval: 2000 • Co-administration with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for RECENT MAJOR CHANGES loss of virologic response and possible resistance and cross resistance. (4) Contraindications (4) 12/2019 WARNINGS AND PRECAUTIONS The following have been observed in patients receiving KALETRA: INDICATIONS AND USAGE • The concomitant use of KALETRA and certain other drugs may result in KALETRA is an HIV-1 protease inhibitor indicated in combination with other known or potentially significant drug interactions. Consult the full antiretroviral agents for the treatment of HIV-1 infection in adults and prescribing information prior to and during treatment for potential drug pediatric patients (14 days and older). (1) interactions. (5.1, 7.3) • Toxicity in preterm neonates: KALETRA oral solution should not be used DOSAGE AND ADMINISTRATION in preterm neonates in the immediate postnatal period because of possible Tablets: May be taken with or without food, swallowed whole and not toxicities. A safe and effective dose of KALETRA oral solution in this chewed, broken, or crushed.
    [Show full text]
  • DESCOVY, and Upon Diagnosis of These Highlights Do Not Include All the Information Needed to Use Any Other Sexually Transmitted Infections (Stis)
    HIGHLIGHTS OF PRESCRIBING INFORMATION once every 3 months while taking DESCOVY, and upon diagnosis of These highlights do not include all the information needed to use any other sexually transmitted infections (STIs). (2.2) DESCOVY safely and effectively. See full prescribing information • Recommended dosage: for DESCOVY. • Treatment of HIV-1 Infection: One tablet taken once daily with or ® without food in patients with body weight at least 25 kg. (2.3) DESCOVY (emtricitabine and tenofovir alafenamide) tablets, for • HIV-1 PrEP: One tablet taken once daily with or without food in oral use individuals with body weight at least 35 kg. (2.4) Initial U.S. Approval: 2015 • Renal impairment: DESCOVY is not recommended in individuals with WARNING: POST-TREATMENT ACUTE EXACERBATION OF estimated creatinine clearance below 30 mL per minute. (2.5) HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS Tablets: 200 mg of FTC and 25 mg of TAF (3) (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION See full prescribing information for complete boxed warning. -------------------------------CONTRAINDICATIONS------------------------------­ DESCOVY for HIV-1 PrEP is contraindicated in individuals with Severe acute exacerbations of hepatitis B (HBV) have been unknown or positive HIV-1 status. (4) reported in HBV-infected individuals who have discontinued products containing emtricitabine (FTC) and/or tenofovir -----------------------WARNINGS AND PRECAUTIONS-----------------------­ disoproxil fumarate (TDF), and may occur with • Comprehensive management to reduce the risk of sexually discontinuation of DESCOVY. Hepatic function should be transmitted infections (STIs), including HIV-1, when DESCOVY is monitored closely in these individuals.
    [Show full text]
  • KALETRA® (Lopinavir/Ritonavir) Capsules (Lopinavir/Ritonavir) Oral Solution
    1 of 57 KALETRA® (lopinavir/ritonavir) capsules (lopinavir/ritonavir) oral solution DESCRIPTION Proprietary name: Kaletra Established name: lopinavir and ritonavir Route of administration: ORAL (C38288) Active ingredients (moiety): Lopinavir (Lopinavir), Ritonavir (Ritonavir) # Strength Form Inactive ingredients 1 133.3 MILLIGRAM, CAPSULE, FD&C Yellow No. 6, gelatin, glycerin, oleic acid, polyoxyl 35 castor oil, 33.3 MILLIGRAM LIQUID FILLED propylene glycol, sorbitol special, titanium dioxide, water (C42954) 2 80 MILLIGRAM, SOLUTION Acesulfame potassium, alcohol, artificial cotton candy flavor, citric acid, 20 MILLIGRAM (C42986) glycerin, high fructose corn syrup, Magnasweet-110 flavor, menthol, natural & artificial vanilla flavor, peppermint oil, polyoxyl 40 hydrogenated castor oil, povidone, propylene glycol, saccharin sodium, sodium chloride, sodium citrate, water KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A- mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir. Lopinavir is chemically designated as [1S-[1R*,(R*), 3R*, 4R*]]-N-[4-[[(2,6- dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro- alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. Its molecular formula is C37H48N4O5, and its molecular weight is 628.80. Lopinavir has the following structural formula: 2 of 57 Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1- methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C37H48N6O5S2, and its molecular weight is 720.95. Ritonavir has the following structural formula: Lopinavir is a white to light tan powder.
    [Show full text]
  • Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
    pharmaceuticals Review Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection Isabella Zanella 1,2,* , Daniela Zizioli 1, Francesco Castelli 3 and Eugenia Quiros-Roldan 3 1 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; [email protected] 2 Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy 3 University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; [email protected] (F.C.); [email protected] (E.Q.-R.) * Correspondence: [email protected]; Tel.: +39-030-399-6806 Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations. Age and comorbidities may explain severity in critical cases and people living with human immunodeficiency virus (HIV) might be at particularly high risk for severe progression. Nonetheless, current data, although sometimes contradictory, do not confirm higher morbidity, risk of more severe COVID-19 or higher mortality in HIV-infected people with complete access to antiretroviral therapy (ART). A possible protective role of ART has been hypothesized to explain these observations. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment; this is also based on previous studies on severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV). Among Citation: Zanella, I.; Zizioli, D.; them, lopinavir/ritonavir, an inhibitor of viral protease, was extensively used early in the pandemic Castelli, F.; Quiros-Roldan, E.
    [Show full text]
  • 1 Epigallocatechin-Gallate and Theaflavin-Gallate Interaction in SARS Cov-2 Spike-Protein Central-Channel with Reference To
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 April 2020 doi:10.20944/preprints202004.0247.v1 Epigallocatechin-gallate and Theaflavin-gallate interaction in SARS CoV-2 spike-protein central-channel with reference to the hydroxychloroquine interaction: Bioinformatics and Molecular Docking Study. Smarajit Maiti1,2* and Amrita Banerjee1 1Departmentof Biochemistry and Biotechnology, Cell and Molecular Therapeutics Laboratory Oriental Institute of Science and Technology, Midnapore, India 2Founder and Secretary, Agricure Biotech Research Society, Epidemiology and Human Health Division, Midnapore- 721101, India *Correspondence Dr. Smarajit Maiti Professor and Head E. Mail: [email protected] Mobile: 9474504269 Dr Amrita Banerjee Assistant Professor E. Mail: [email protected] Short title: Tea-flavonoids bind COVID-19 spike-proteins Conflict of interests: none Funding: Partially funded by Dept of Science and Technology, Govt. Of West Bengal, INDIA Abstract SARS CoV-2 or COVID-19 pandemic global-outbreak created the most unstable situation of human health-economy. Last two decades different parts of the word experienced smaller or bigger outbreak related to human-coronaviruses. The spike- glycoproteins of the COVID-19 (similar to SARS-CoV) attach to the angiotensin-converting-enzyme (ACE-2) and transit over a stabilized open-state for the viral-internalization to the host-cells and propagate with great efficacy. Higher rate of mutability makes this virus unpredictable/less-sensitive to the protein/nucleic-acid based-drugs.
    [Show full text]
  • 1.0 Abstract
    Lopinavir/Ritonavir PMOS P11-021 Study Results – Final 1.0 Abstract Title Use of KALETRA in combination with new substances in adult HIV-infected patients: Data from the German multicenter PROTEKT cohort Keywords HIV, lopinavir/ritonavir, LPV/r, PROTEKT Rationale and Background PROTEKT is a non-interventional cohort study including ART-naïve and treatment-experienced HIV-1-infected patients receiving cART including LPV/r plus an antiretroviral drug not of the NRTI class, i.e., an integrase inhibitor (INI), a chemokine receptor type 5 (CCR5) antagonist, or second-generation NNRTI. There were no restrictions concerning additional antiretrovirals. Assignment of a patient to a particular cART was part of routine clinical care and was independent from the conduct of PROTEKT. Ethics approval was obtained prior to initiation of the study. Research Question and Objectives The goal of this study was to observe and collect data on the usage, dosing, tolerability, and efficacy of KALETRA® tablets in combination with other new agents. The primary objective was the evaluation of tolerability when using lopinavir/ritonavir in combination with an INI, a CCR5 antagonist, or a second-generation NNRTI. Other objectives included immunologic responses (i.e., the change in CD4 T-cell count), the characterization of baseline resistance and the development of resistance, virologic outcomes and the durability of the LPV/r-based regimens. Study Design Retro- and prospective, multicenter, observational, non-interventional cohort study. 17 Lopinavir/Ritonavir PMOS P11-021 Study Results – Final Setting Routine clinical practice in Germany Subjects and Study Size, Including Dropouts: The study population consisted of ART-naïve and treatment-experienced HIV-infected patients initiated on new LPV/r-based combination regimens.
    [Show full text]
  • Identification of Dietary Molecules As Therapeutic Agents to Combat COVID-19 Using Molecular Docking Studies
    Identication of Dietary Molecules as Therapeutic Agents to Combat COVID-19 Using Molecular Docking Studies Mohammad Faheem Khan ( [email protected] ) Era' Lucknow medical College, Era University, Lucknow-226003, India https://orcid.org/0000-0002- 1943-7160 Mohsin Ali Khan Era’ Lucknow Medical College, Era University, Sarfarazganj, Hardoi Road, Lucknow-226003, UP, India Zaw Ali Khan Era’ Lucknow Medical College, Era University, Sarfarazganj, Hardoi Road, Lucknow-226003, UP, India Tanveer Ahamad Era’ Lucknow Medical College, Era University, Sarfarazganj, Hardoi Road, Lucknow-226003, UP, India Waseem Ahmad Ansari Era’ Lucknow Medical College, Era University, Sarfarazganj, Hardoi Road, Lucknow-226003, UP, India Research Article Keywords: SARS-CoV-2, EGCG, COVID-19, Dietary Molecules, Molecular Docking Posted Date: March 27th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-19560/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Identification of Dietary Molecules as Therapeutic Agents to Combat COVID-19 Using Molecular Docking Studies Mohammad Faheem Khan*, Mohsin Ali Khan, Zaw Ali Khan, Tanveer Ahamad, Waseem Ahmad Ansari Department of Biotechnology, Era’ Lucknow Medical College, Era University, Sarfarazganj, Hardoi Road, Lucknow-226003, UP, India Abstract Recently, a new and fatal strain of coronavirus named as SARS-CoV-2 (Disease: COVID-19) appeared in Wuhan, China in December of 2019. Due to its fast growing human to human transmission and confirmed cases in nearly every country, it has been declared as pandemic by World Health Organisation (WHO) on 11 March 2020. Till now, there is no therapy such as vaccines and specific therapeutic agents available globally.
    [Show full text]
  • Application for Inclusion of Emtricitabine and Tenofovir Alafenamide Fixed Dose Combination Tablets (Descovy®) on the WHO Model List of Essential Medicines
    Application for Inclusion of Emtricitabine and Tenofovir Alafenamide Fixed Dose Combination Tablets (Descovy®) on the WHO Model List of Essential Medicines Submitted by Gilead Sciences Inc. December 2016 Gilead Sciences Inc. 333 Lakeside Drive Foster City California 94404 USA Gilead Sciences Submission Reference number: GSI-DSY-161201 1 Application for inclusion of Descovy tablets in the WHO Model List of Essential Medicines, December 2016 Contents 1. Summary statement of the proposal for inclusion ................................................... 5 2. Name of the focal point in WHO submitting or supporting the application ................. 7 3. Name of the organization(s) consulted and/or supporting the application ................. 7 4. International Nonproprietary Name (INN, generic name) of the medicine ................. 7 5. Formulation proposed for inclusion ........................................................................ 8 6. International availability ....................................................................................... 9 7. Listing type requested ........................................................................................ 11 8. Information supporting the public health relevance ............................................... 12 8.1 Epidemiological information on disease burden 12 9. Treatment details ............................................................................................... 15 9.1 Indications and usage 15 9.2 Dosage and administration 16 9.2.1 Special populations 16
    [Show full text]
  • Lopinavir; Ritonavir (All Populations Monograph)
    3/17/2020 Clinical Pharmacology powered by ClinicalKey Lopinavir; Ritonavir (All Populations Monograph) Indications/Dosage expand all | collapse all Labeled human immunodeficiency virus (HIV) infection Off-Label, Recommended coronavirus disease 2019 (COVID-19) † severe acute respiratory syndrome coronavirus 2 (SARS- human immunodeficiency virus (HIV) prophylaxis † CoV-2) infection † † Off-label indication NOTE: HIV guidelines recommend consideration be given to avoiding use of lopinavir; ritonavir-containing regimens in patients at high risk for cardiovascular adverse events.[46638] Initiation of therapy for HIV treatment: [46638] [23512] [42452] For adults, initiation of treatment immediately (or as soon as possible) after HIV diagnosis is recommended in all patients to reduce the risk of disease progression and to prevent the transmission of HIV, including perinatal transmission and transmission to sexual partners. Starting antiretroviral therapy early is particularly important for patients with AIDS-defining conditions, those with acute or recent HIV infection, and individuals who are pregnant; delaying therapy in these subpopulations has been associated with high risks of morbidity, mortality, and HIV transmission. Antiretroviral drug-resistance testing: Genotypic drug-resistance testing is recommended prior to initiation of therapy in all antiretroviral treatment- naive patients and prior to changing therapy for treatment failure. Phenotypic resistance testing may be used in conjunction with the genotypic test for patients with known or suspected complex drug-resistance mutation patterns. HIV-1 proviral DNA resistance testing is available for use in patients with HIV RNA concentrations below the limits of detection or with low-level viremia (i.e., less than 1,000 copies/mL), where genotypic testing is unlikely to be successful; however, the clinical utility of this assay has not been fully determined.
    [Show full text]
  • Is There a True Difference in Efficacy and Safety?
    Journal of Virus Eradication 2018; 4: 73–80 ORIGINAL RESEARCH Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? Andrew Hill1*, Sophie L Hughes2, Dzintars Gotham2 and Anton L Pozniak3 1 Department of Pharmacology and Therapeutics, University of Liverpool, UK 2 Faculty of Medicine, Imperial College London, UK 3 Chelsea and Westminster Hospital NHS Foundation Trust, London, UK Abstract Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by 25–37%. When combined with RTV or COBI, the dose of tenofovir alafenamide (TAF) is lowered from 25 mg to 10 mg daily, but the TDF dose is maintained at 300 mg daily. Objective: To assess the differences in safety and efficacy between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in regimens with and without the pharmacokinetic boosters RTV and COBI. Methods: A PubMed/Embase search inclusive of dates up to 17 July 2017 identified 11 randomised head-to-head trials (8111 patients) of TDF versus TAF. The Mantel–Haenszel method was used to calculate pooled risk differences and 95% confidence intervals using random-effects models. A pre-defined sub-group analysis compared TAF with TDF, either when boosted with RTV or COBI, or when unboosted. Results: Nine clinical trials compared TAF and TDF for treatment of HIV-1 and two were for hepatitis B treatment. The eleven clinical trials documented 4574 patients with boosting RTV or COBI in both arms, covering 7198 patient-years of follow-up.
    [Show full text]
  • Design, Synthesis, and Structure-Activity Relationship Investigation of 3’,4’-Disubstituted Pyranochromone Derivatives with Diverse Biological Activities
    DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP INVESTIGATION OF 3’,4’-DISUBSTITUTED PYRANOCHROMONE DERIVATIVES WITH DIVERSE BIOLOGICAL ACTIVITIES Ting Zhou A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Eshelman School of Pharmacy. Chapel Hill 2010 Approved by Kuo-Hsiung Lee, PhD (Advisor) Kenneth F. Bastow, PhD Jian Liu, PhD Qian Shi, PhD Chin-Ho Chen, PhD i ©2010 Ting Zhou ALL RIGHTS RESERVED ii ABSTRACT TING ZHOU: DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP INVESTIGATION OF 3’,4’-DISUBSTITUTED PYRANOCHROMONE DERIVATIVES WITH DIVERSE BIOLOGICAL ACTIVITIES (Under the direction of Kenan Professor Kuo-Hsiung Lee) The overall goals of this research are to design and synthesize novel 3’,4’- disubstituted pyranochromone derivatives, to evaluate their anti-HIV activity and chemosensitizing potency, to elucidate structure-activity relationships (SAR), and to discover novel chemical entities. 3’R,4’R-Di-camphanoyl-khellactone analogs (DCKs) was first identified in our laboratory with high anti-HIV activity against wild-type HIV strain early in 1994. Using SAR-directed strategy, 3’R,4’R-di-camphanoyl-pyranochromone analogs (DCPs) were synthesized and evaluated in a continuing study, which showed high potency against both wild-type and multi-RT inhibitor-resistant strains. Mechanism study of DCK and its derivatives suggested that the compounds target HIV-RT in a unique way, by inhibiting its DNA-dependent DNA polymerase activity. A microwave-assisted one-pot reaction was first developed in our study and successfully applied in the preparation of 2’,2’-dimethyl-chromone motifs which were iii key intermediates in DCK and DCP derivatives.
    [Show full text]
  • TABLE of CONTENTS LOPINAVIR and RITONAVIR Tablets, for Oral Use
    TABLE OF CONTENTS LOPINAVIR and RITONAVIR tablets, for oral use 2 HIGHLIGHTS OF PRESCRIBING INFORMATION 2 FULL PRESCRIBING INFORMATION 3 1 INDICATIONS AND USAGE 3 2 DOSAGE AND ADMINISTRATION 3 3 DOSAGE FORMS AND STRENGTHS 6 4 CONTRAINDICATIONS 6 5 WARNINGS AND PRECAUTIONS 7 6 ADVERSE REACTIONS 10 7 DRUG INTERACTIONS 16 8 USE IN SPECIFIC POPULATIONS 24 10 OVERDOSAGE 27 11 DESCRIPTION 27 12 CLINICAL PHARMACOLOGY 29 13 NONCLINICAL TOXICOLOGY 37 14 CLINICAL STUDIES 38 16 HOW SUPPLIED/STORAGE AND HANDLING 43 17 PATIENT COUNSELING INFORMATION 44 MEDICATION GUIDE 46 HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------------CONTRAINDICATIONS----------------------------- Hypersensitivity to lopinavir and ritonavir (e.g., toxic epidermal These highlights do not include all the information needed to use necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, LOPINAVIR AND RITONAVIR TABLETS safely and effectively. angioedema) or any of its ingredients, including ritonavir. (4) See full prescribing information for LOPINAVIR AND RITONAVIR Co-administration with drugs highly dependent on CYP3A for TABLETS. clearance and for which elevated plasma levels may result in serious and/or life-threatening events. (4) LOPINAVIR and RITONAVIR tablets, for oral use Co-administration with potent CYP3A inducers where significantly Initial U.S. Approval: 2000 reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and --------------------------INDICATIONS AND USAGE------------------------ cross resistance. (4) Lopinavir and ritonavir is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 ----------------------WARNINGS AND PRECAUTIONS-------------------- infection in adults and pediatric patients (6 months and older weighing at The following have been observed in patients receiving lopinavir and least 15 kg).
    [Show full text]